Prokidney provide specialized treatment for chronic kidney disease.
Business Model: Non-Profit
Revenue: $0
Employees: 11-50
Address: 3929 Westpoint Blvd.
City: Winston-Salem
State: NC
Zip: 27103
Country: US
ProKidney offers treatment of chronic kidney disease (CKD) through innovations in cellular therapy. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program.
Contact Phone:
Contact Email:
Listed Exchange:
NYSE
IPO Date:
7/12/2022
Ticker Symbol:
PROK
Amount Raised:
$597M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 7/2022 | IPO SPAC | - | 7/2022 | Post-IPO Equity | 2 | $205M |
Social Capital Suvretta Capital Management Social Capital Suvretta Capital Management |
7/2022 | IPO SPAC | - |
|
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|